Join Date
October 2024
Gender
Not Specified
Age
Not Specified
About Will Olsen
Co-Founder & CEO of Engage Bio
Companies & Work
Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.
Engage’s Tethosome platform solves the two key hurdles that have held back the field of non-viral DNA: potency and toxicity. Using proven LNP technology, we deliver a therapeutic DNA and an mRNA encoding our proprietary Tethosome protein. This protein localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our Tethosome platform is invisible to immune sensors which detect foreign DNA and which can cause lethal immune reactions. This allows us to safely deliver potent DNA, re-dose when needed, and titrate expression to optimal levels.
Engage’s Tethosome platform solves the two key hurdles that have held back the field of non-viral DNA: potency and toxicity. Using proven LNP technology, we deliver a therapeutic DNA and an mRNA encoding our proprietary Tethosome protein. This protein localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our Tethosome platform is invisible to immune sensors which detect foreign DNA and which can cause lethal immune reactions. This allows us to safely deliver potent DNA, re-dose when needed, and titrate expression to optimal levels.
